View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 19, 2022

Ascentage’s drug shows potential to treat Covid-19 in preclinical study

Olverembatinib showed increased Omicron-NTD-mediated cytokine release suppression compared with ponatinib and baricitinib.

Ascentage Pharma has reported that its drug, olverembatinib (HQP1351), demonstrated a therapeutic potential to hinder SARS-CoV-2 omicron-mediated cytokine release in a preclinical study.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The study was carried out by scientists from Fred Hutchinson Cancer Research Center, Seattle, US.

Currently, olverembatinib is approved to treat adults with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukaemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation, in China.

Researchers have found that the N-terminus domain (NTD) of the spike protein of the SARS-CoV-2 virus can facilitate inflammatory cytokine release in monocytes and PBMCs. 

The team also found in the study that the NTD of the Omicron variant can elicit the release of several cytokines, including IL-1β, IL-6, and the tumour necrosis factor (TNF-α), in PBMCs. 

Treatment with olverembatinib demonstrated increased Omicron-NTD-mediated cytokine release suppression versus ponatinib and baricitinib.

Baricitinib is a Food and Drug Administration (FDA)-approved drug to treat Covid-19.

Furthermore, olverembatinib hinders the activity of various kinases involved in cytokine signalling to slow down the Omicron-NTD-mediated cytokine release and lower inflammations. 

The latest data shows that agents, such as olverembatinib, that act on various kinases needed for the virus and variant mediated cytokine release could be an option for moderate to severe Covid-19 treatment.

Olverembatinib is presently being analysed in various trials in the US and China to treat CML, acute lymphocytic leukaemia and gastrointestinal stromal tumour.

Ascentage Pharma chairman and CEO Dr Dajun Yang said: “Olverembatinib is a drug candidate we have studied for many years. 

“As the world’s second third-generation BCR-ABL TKI entering clinical development in the US, and one of the few China-developed novel drug candidates positioned for the global market from the very beginning, olverembatinib has demonstrated excellent efficacy and safety, leading to the approval for the treatment of drug-resistant CML in China last year.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology